Akari’s complement and leukotriene inhibitor, nomacopan, demonstrated improved survival (80% vs. 30%) in a preclinical model of traumaA follow-on program …
Akari Therapeutics to Present at BIO CEO & Investor Conference
NEW YORK and LONDON, February 11, 2022 – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to …
[Read more...] about Akari Therapeutics to Present at BIO CEO & Investor Conference
Q&A with Miles Nunn, Chief Scientific Officer
1. Can you give us an outline of your role at Akari? Scientific input and oversight to all areas of Akari’s work including strategic direction, regulatory …
[Read more...] about Q&A with Miles Nunn, Chief Scientific Officer
FDA Agrees to Use of New Higher-Yielding Manufacturing Process for Nomacopan in Pivotal Clinical Studies
New manufacturing process increases the final yield of nomacopan by at least 5-fold thereby significantly lowering the cost of goods for clinical studies and …
Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
NEW YORK and LONDON, January 4, 2022 – Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to …
[Read more...] about Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference
